J. Fox

发表

Cardiovascular gene therapy: current concepts.

J. Fox, 1996, Therapeutic drug monitoring.

Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.

I. Graef, Fang Liu, R. Zamboni, 2018, Journal of medicinal chemistry.

Cardiovascular Gene Therapy: Principles and Clinical Applications

J. Fox, 1998 .

The JNC 7 Approach Compared to Conventional Treatment in Diabetic Patients With Hypertension: A Double‐Blind Trial of Initial Monotherapy vs. Combination Therapy

G. Bakris, J. Fox, A. Lewin, 2004, Journal of clinical hypertension.

Should rosuvastatin be withdrawn from the market?

G. Olsson, J. Fox, 2004, The Lancet.

Apoptosis and the Cardiovascular System

J. Fox, V. Patel, 1998 .

Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis.

M. Maurer, J. Fox, R. Mussinelli, 2019, Journal of cardiac failure.

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups

B. Gagnon, J. Fox, D. Rintell, 2020, Orphanet Journal of Rare Diseases.

First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers

J. Fox, J. Jernelius, Jennifer L. Hellawell, 2019, Clinical pharmacology in drug development.

Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.

T. Yanase, J. Sasaki, N. Yamada, 2007, Atherosclerosis.

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy

E. Ashley, S. Colan, C. Caleshu, 2018, Circulation.

Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy.

B. Devreese, R. Samulski, S. Gray, 2013, Human gene therapy.

Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme™

J. Fox, H. Schuster, 2004, Expert opinion on pharmacotherapy.

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

S. Solomon, K. Mahaffey, T. Povsic, 2017, Cardiovascular Drugs and Therapy.

Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.

Sanjiv J. Shah, R. Falk, D. Judge, 2019, Journal of the American College of Cardiology.

Abstract 16842: Obstructive Hypertrophic Cardiomyopathy: Initial Single Ascending Dose Data in Healthy Volunteers and Patients

E. Ashley, K. Mahaffey, J. Ritter, 2016 .

The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy

John D Seeger, E. Ming, J. Fox, 2006, Pharmacoepidemiology and drug safety.

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.

J. Manson, P. Ridker, J. C. Fox, 2001, Journal of the American College of Cardiology.

AG10, A Novel, Potent and Selective Transthyretin Stabilizer, is Well Tolerated at Doses Resulting in Target Therapeutic Blood Levels, and Demonstrates Clinical Proof-of-Concept in Healthy Volunteers

J. Fox, J. Jernelius, Jennifer L. Hellawell, 2018, Journal of Cardiac Failure.

Abstract 19616: AG10 Stabilizes Pathogenic TTR Variants With High Potency - Potential for an Effective Treatment for TTR Cardiomyopathy

I. Graef, D. Judge, M. Liedtke, 2017 .

Rosuvastatin–warfarin drug interaction

G. Olsson, J. Fox, 2004, The Lancet.